AUTHOR INDEX

(P = Proceedings)

ABBOT N.C. *see* BARNES J.
ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man *in vivo*, 271
ABE J. *see* NISHI S.
ACKLAND M., HYLAND R., JONES B., TYMAN C. & SMITH D. The interaction of terfenadine with CYP2D6: an *in vitro* and molecular modelling study, 513P
ADAMS C.A. *see* ANDERSON G.D.
ADZET T. *see* VÁZQUEZ M.
AHOKOSHI O., IRJALA K., HUUPPONEN R., HALONEN K., SALMINEN E. & SCHEININ H. Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study, 141
AHR G. *see* MÜCK W.
AITCHISON T. *see* GRANT S.
AL-SARRAJ S. *see* COTTER D.
ALTORF B. *see* VAN GERVEN J.M.A.
ALVÁN G. *see* WAKELKAMP M.
ALVES O. *see* SERRA H.A.
ANDERSON G.D., AWAN A.B., ADAMS C.A., TEMKIN N.R. & WINN H.R. Increases in metabolism of valproate and excretion of 6β-hydroxycortisol in patients with traumatic brain injury, 101
ANDERSSON T., HOLMBERG J., RÖHSS K. & WALAN A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors omeprazole, lansoprazole, and pantoprazole, 369
ANDERTON B. *see* COTTER D.
ANDREWS H. *see* DURSUN S.M.
ANDREWS J. *see* KENWORTHY K.E.
ANGGARD E.E. *see* MACCALLUM H.
ANKLESARIA B.S. *see* BHATHENA R.K.
ANUMBA D.O.C., ROBSON S.C. & FORD G.A. Flow-mediated nitric oxide activity in the forearm vasculature of pregnant and nonpregnant women, 190P
APLIN R. *see* DELGODA R.
APSELOFF G. *see* LISTON T.E.
ASADA A. *see* NISHI S.
ASCIERTO H. *see* SERRA H.A.
ASHTON M. *see* SIDHU J.S.
AWAN A.B. *see* ANDERSON G.D.
AZAZ-LIVSHITS T., LEVY M. SADAN B., SHALIT M., GEISSLINGER G. & BRUNE K. Computerized surveillance of adverse drug reactions in hospital: pilot study, 309
AZIZ I., DEVLIN M.M. McFARLANE L.C. & LIPWORTH B.J. Effect of high dose inhaled budesonide on systemic-β_2 adrenoceptor (b_2-AR) sensitivity to salbutamol in patients receiving regular inhaled eformoterol, 201P
AZIZ I., TAN K.S., DEVLIN M.M. & LIPWORTH B.J. Subsensitivity to bronchoprotection against adenosine monophosphate (AMP) challenge following regular once daily formoterol, 201P

BABOOLAL S. *see* NEWTON-SAVAGE F.A.O.
BACK D.J. & BRECKENRIDGE A. Editorial, 93
BACK D.J. *see* BARRY M.
BACK D.J. *see* BARRY M.G.
BACK D.J. *see* EAGLING V.A.
BACK D.J. *see* GENTILE D.M.
BACK D.J. *see* HOGGARD P.G.
BACK D.J. *see* JONES T.E.
BACK D.J. *see* KEWN S.
BACK D.J. *see* PIRMOHAMED M.
BACK D.J. *see* SALES S.D.
BACRI A.M. *see* JOANNIDES R.
BANG U., NYBERG L., ROSENBORG J. & VIBY-MOGENSEN, J. Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase, 479
BARDIN P.G., DORWARD M.A., LAMPE F.C., FRANKE B. & HOLGATE S.T. Effect of selective phosphodiesterase 3 inhibition of the early and late asthmatic responses to inhaled allergen, 387
BARNES J., MILLS S.Y., ABBOT N.C., WILLOUGHBY M. & ERNST E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies, 496
BARRY M. *see* HOGGARD P.G.
BARRY M., MULACHY F. & BACK D.J. Antiretroviral therapy for patients with HIV disease, 221
BARRY M.G. *see* HOGGARD P.G.
BARRY M.G. *see* KEWN S.
BARRY M.G., MERRY C., LLOYD J., HALIFAX K., CAREY P., MULCAHY F. & BACK D.J. Variability in trough plasma saquinavir concentrations in HIV patients—a case for therapeutic drug monitoring, 501
BATEMAN D.N. *see* McELHATTON P.R.
BATTY K.T., THU L.T.A., DAVIS T.M.E., ILETT, K.F., MAI T.X., HUNG N.C., TIEN N.P., POWELL S.M., THIEN H.V., BINH T.Q. & KIM N.V. A pharmakokinetic and pharmacodynamic study of intravenous oral artesunate in uncomplicated falciparum malaria, 123
BAYLISS M.K. *see* CARLILE D.J.
BEERAHEE A. *see* TAYLOR A.C.
BELZ G. *see* MALERCZYK C.
BENNETT J.A., THOMPSON COON J., PAVORD I.D., WILDING P.J. & TATTERSFIELD A.E. The airway effects of stopping regular oral theophylline in patients with asthma, 402
BENZIE I.F.F. & TOMLINSON B. Antioxidant power of angiotensin-converting enzyme inhibitors *in vitro*, 168
BERKOVITCH M., PAPADOURIS D. & SHAW D. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease, 605
BERLIN I., WAROT D., LEGOUT V., GUILLEMANT S., SCHOLLNHAMMER G. & PUECH A.J. Blunted 5-HT_{1A} receptor agonist-induced ACTH and cortisol responses following chronic ipsapirone and fluoxetine administration: a double-blind placebo-controlled study in healthy volunteers, 210P
BESA C., BUSS D.C., TARIQ S., CAMPBELL I.A. & ROUTLEDGE P.A. The pharmacokinetics of antipyrine in patients with cystic fibrosis, 202P
BESA C., BUSS D.C., TARIQ S., CAMPBELL I.A. & ROUTLEDGE P.A. The plasma protein binding of lignocaine and phenytoin in cystic fibrosis, 202P
BHATHENA R.K., ANKLESARIA B.S., GANATRA A.M. & PINTO R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins, 170
BINH T.Q. *see* BATTY K.T.
BIRD D. *see* KUTCHER D.
BIRKETT D.J. *see* MINERS J.O.
BITSIOS P., LANGLEY R.W., TAVERNOR S., PYYKKÖ K., SCHEININ M., SZABADI E. & BRADSHAW C.M. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man, 551
BOISSEL J.P. *see* LECHAT P.
BOON N.A. *see* NEWBY D.E.
BOWERY N.G. *see* TURNER H.L.
BRACCHI R. *see* NEWTON-SAVAGE F.A.O.
BRADSHAW C.M. *see* ABDELMAWLA A.H.
BRADSHAW C.M. *see* BITSIOS P.
BRECKENRIDGE A. *see* BACK D.J.
BREFEL C., THALAMAS C., RAYET S., LOPEZ-GIL A., FITZPATRICK K., BULLMAN S., CITERONE D.R., TAYLOR A.C., MONTASTRUC J.L. & RASCOL O. Effect of food on the

© 1998 Blackwell Science Ltd

pharmacokinetics of ropinirole in parkinsonian patients, 412
BREITHAUPT-GRÖGLER K. *see* MALERCZYK C.
BRETT S.E., FISHER I., GINKS M., HAYTER S., RITTER J.M. & CHOWIENCZYK P.J. Converting enzyme inhibition and effect of exercise on prostacyclin biosynthesis in healthy humans, 190P
BRODDE O-E. *see* JAKUBETZ J.
BROOKS C. *see* WEEKES L.M.
BROWERS J.R.B.J. *see* DENEER, V.H.M.
BROWN P.D. *see* MILLAR A.W.
BRUNE K. *see* AZAZ-LIVSHITS T.
BRUNO R. *see* RABBONE I.
BRUSSE D. *see* FROMM M.F.
BULLMAN S. *see* BREFEL C.
BURGGRAAF J. *see* FAAIJ R.A.
BURGGRAAF J. *see* SCHOEMAKER R.C.
BURGGRAAF J., SCHOEMAKER R.C., KROON J.M. & COHEN A.F. The influence of nifedipine and captopril on liver blood flow in healthy subjects, 447
BURGMANN H. *see* THALHAMMER F.
BUSS D.C. *see* BESA C.
BUTZER R. *see* MALERCZYK C.

CALDWELL J. *see* SOMCHIT N.
CALVERT R. *see* WOLFF K.
CAMPBELL I.A. *see* BESA C.
CAMPESTRINI J. *see* LECAILLON J.B.
CAREY P. *see* BARRY M.G.
CARLILE D.J., BAYLISS M.K. & HOUSTON J.B. Prediction of intrinsic clearance of CYP2C9 substrates in man using hepatic microsomes: importance of K_m, 512P
CARTER E.C. *see* COLLIER D.J.
CAVANAGH S.P. *see* ESTDALE S.E.
CAVANAGH S.P., ESTDALE S.E., PARKIN S.M., RAWSTRON A., GOUGH M.J., GRAHAM A. & HOMER-VANNIASINKAM S. The cytokine response to perioperative leucodepletion during limb salvage surgery, 521P
CHADWICK A.P., McKILLOP D. & HOUSTON J.B. Inhibition of rat cytochrome P450-dependent metabolism by ketoconazole and fluconazole *in vitro*, 521P
CHAMBERLAIN N. *see* MAHMOOD I.
CHARLETT A. *see* PURKISS A.G.
CHIBA K. *see* KOBAYASHI K.
CHOISY H. *see* TRENQUE T.
CHONG S. *see* TURNER H.L.
CHOONARA I. *see* PARKER A.C.
CHOWIENCZYK P.J. *see* BRETT S.E.
CHOWIENCZYK P.J. *see* MACCALLUM H.
CHRISTIE J. *see* GRANT S.
CIFUENTES L. *see* COLLIER D.J.
CITERONE D.R. *see* BREFEL C.
CITERONE D.R. *see* TAYLOR A.C.
CLARK D.J. *see* LIPWORTH B.J.
CLARKE S.E. *see* KENWORTHY K.E.
COCKCROFT J.R. *see* HALL I.P.
COHEN A.F. *see* BURGGRAAF J.
COHEN A.F. *see* FAAIJ R.A.
COHEN A.F. *see* SCHOEMAKER R.C.
COHEN A.F. *see* VAN GERVEN J.M.A.
COLLIER D.J., ROSENBERG M.E., MILLEDGE J.S., CIFUENTES L., PELLING C.W.A., CARTER E.C., SWENSON E.R., JOHNSTON A. & HEDGES A. Actions of carbonic anhydrase inhibitors in man, 200P
COLLINS A. *see* McELHATTON P.R.
COMBES O. *see* SIMON N.
COMPAGNON P. *see* JOANNIDES R.
COMPAGNON P. *see* MOORE N.
COMPAGNONE D. On Behalf Of The German Hypertension Study Group, *see* SCHOLZE J.
CONG L.D. *see* SIDHU J.S.
CONKLYN M.J. *see* LISTON T.E.
CONNELL J.M.C. *see* PETRIE J.R.
CORNISH A.G. *see* MILLAR A.W.
COTTER D., KERWIN R., AL-SARRAJ S., DOSHI B., LOVESTONE S., ANDERTON B. & EVERALL I. Alterations in intraneural β- and γ-catenins in the hippocampus in schizophrenia, 203P
CRAGGS M.D. *see* SULTANA S.R.
CROCKETT T.C. *see* STRACHAN F.E.
CRUDEN N.L., NEWBY D.E., STRACHAN F.E. & WEBB D.J. Comparison of peripheral vascular ET_A and ET_B receptor antagonism *in vivo* in man, 192P
CUNZE T. *see* GLEITER C.H.
CURTO M. *see* RABBONE I.

DAHLQVIST R. *see* SPIGSET O.
DAILLY E. *see* SIMON N.
DARGIE H.J. *see* GRANT S.
DAVIE A. *see* GRANT S.
DAVIES S.J.C. *see* GHAHRAMANI P.
DAVIS T.M.E. *see* BATTY K.T.
DAWES M. *see* MACCALLUM H.
DAY R.O. *see* WEEKES L.M.
DELGODA R., SINCLAIR J.C., NOBLE M.E.M., APLIN R., LIAN L-Y & SIM E. Drug metabolism, acetylation, structure, 505P
DENEER V.H.M., LIE-A-HUEN L., KINGMA J.H., PROOST J.H., KELDER J.C. & BROUWERS J.R.B.J. Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects, 485
DEVLIN M.M. *see* AZIZ I.
DEVOTO F.M. *see* SERRA H.A.
DILGER K. *see* FROMM M.F.
DOBBS R.J. *see* PURKISS A.G.
DONALDSON T.J.D. *see* McELHATTON P.R.
DORANGEON P.H. *see* TRENQUE T.
DORNER G. *see* WOLZT M.
DORWARD M.A. *see* BARDIN P.G.
DOSHI B. *see* COTTER D.
DRICI M-D., WANG W.X., WOOSLEY R.L., FLOCKHART D.A. & THOMAS S.M.L. Effects of antipsychotic drugs on cardiac repolarization and the QT interval, 187P
DUPOUY D. *see* TRENQUE T.
DURSUN S.M. *see* KUTCHER D.
DURSUN S.M., TIN N., SZEMIS A., ANDREWS H. & REVELEY M.A. The effects of clozapine on serum total cholesterol and some related lipid levels in schizophrenia: a prospective study, 205P
DUSCI L.J. *see* ILETT, K.F.
DUSCI L.J. *see* KRISTENSEN J.H.

EAGLING V.A., TJIA J.F. & BACK D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes, 107
EASTMOND R. *see* YOUNG M.A.
EICHELBAUM M. *see* FROMM M.F.
EICHLER H.G. *see* WOLZT M.
ELLIOTT H.L. *see* PETRIE J.R.
ERNST E. Homoeopathy: Past, present and future: reply to Vithoulkas' letter, 613
ERNST E. *see* BARNES J.
ERNST E. Homoeopathy: past, present and future, 613
ESCOLANO S. *see* LECHAT P.
ESTDALE S.E., CAVANAGH S.P., HOMER-VANNIASINKAM S. & PARKIN S.M. Cytokine assay kits in clinical trials: a comparative study, 523P
ESTDALE S.E., CAVANAGH S.P., REED A., GOUGH M.J., GRAHAM A. & HOMER-VANNIASINKAM S. The hidden hazards of blood transfusion during abdominal aortic aneurysm (AAA) repair, 522P
EVANS C. *see* McELHATTON P.R.
EVE M.D. *see* ROUTLEDGE P.A.
EVERALL I. *see* COTTER D.

FAAIJ R.A., BURGGRAAF J., SCHOEMAKER H.C., STIEKEMA J., SIEGERT C. & COHEN A.F. The influence of renal function on the pharmacokinetics (PK) and pharmacodynamics of the novel antithrombotic agent Org31540/SR90107A, 211P
FATTINGER K.E. *see* KUPFERSCHMIDT H.H.T.
FENG H.J., HUANG S.L., WANG W. & ZHOU H.H. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M_1 mutation of CYP2C19 and gene dose, 27
FERRO C.J. *see* NEWBY D.E.
FISHER A., ROBINSON P. & RITTER J.M. Dose-dependent inhibition by tirofiban of platelet aggregation in response to an antibody (P256) directed against glycoprotein IIb/IIa receptors of human platelets, 196P
FISHER I. *see* BRETT S.E.
FITZPATRICK K. *see* BREFEL C.
FLOCKHART D.A. *see* DRICI M-D.
FOLLATH F. *see* KUPFERSCHMIDT, H.H.T.

© 1998 Blackwell Science Ltd

FORD G.A. *see* ANUMBA D.O.C.
FOX K.A.A. *see* NEWBY D.E.
FRANCIS R.M. Management of established osteoporosis, 95
FRANKE B. *see* BARDIN P.G.
FRASS M. *see* THALHAMMER F.
FROMM M.F., DILGER K., BRUSSE D., KROEMER H.K., EICHELBAUM M. & KLOTZ U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction, 247
FUCHS B. *see* JAKUBETZ J.
FUCHS B. *see* MALERCZYK C.
FUELL D. *see* TAYLOR A.C.

GALLOWAY W.A. *see* MILLAR A.W.
GAMBA S. *see* RABBONE I.
GANATRA A.M. *see* BHATHENA R.K.
GARCIA RODRIGUEZ L.A. & GUTTHANN S.P. Use of the UK General Practice Database for pharmacoepidemiology, 419
GAZIS A.G. *see* HALL I.P.
GEISSLINGER G. *see* AZAZ-LIVSHITS T.
GENTILE D.M., HALIFAX K.L. & BACK D.J. Role of CYP2C in the bioactivation of the oral contraceptive steroid desogestrel *in vitro*, 515P
GERTZ B.J. *see* NEWBY D.E.
GESCHER A., PASTORINO U., PLUMMER S.M. & MANSON M.M. Suppression of tumour development by substances derived from the diet—mechanisms and clinical implications, 1
GHAHRAMANI P., DAVIES S.J.C., YEO W.W., JACKSON P.R., LENNARD M.S., TUCKER G.T. & RAMSAY L.E. Influence of genetic polymorphism on the pharmacokinetics of amitriptyline and nortriptyline: a NONMEM analysis, 507P
GHAHRAMANI P., YEO W.W., JACKSON P.R. & RAMSAY L.E. Comparison between methods of estimating creatinine clearance from serum creatinine: a simulation study, 209P
GIBBS C.R. & LIP G.Y.H. Do we still need dipyridamole?, 323
GILL H.J. *see* PIRMOHAMED M.
GINKS M. *see* BRETT S.E.
GLEITER C.H., SCHREEB K.H., GOLDBACH S., HERZOG S., CUNZE T. & KUHN W. Fenoterol increases erythropoietin concentrations during tocolysis, 157
GODBILLON J. *see* LECAILLON J.B.
GOLDBACH S. *see* GLEITER C.H.
GOLDBERG M.R. *see* STRACHAN F.E.
GOLDIN R.D. *see* SOMCHIT N.
GORDON K.A. *see* McELHATTON P.R.
GORF A. *see* JAKUBETZ J.
GOUGH M.J. *see* CAVANAGH S.P.
GOUGH M.J. *see* ESTDALE S.E.
GRAHAM A. *see* CAVANAGH S.P.
GRAHAM A. *see* ESTDALE S.E.
GRANBERG K. *see* SPIGSET O.
GRANT M.H. *see* NING J.
GRANT M.H. *see* RODGERS E.H.
GRANT M.H. *see* SHI Q.
GRANT S., MCMURRAY J., AITCHISON T., MCDONAGH T., CHRISTIE J., DAVIE A. & DARGIE H.J. The reproducibility of symptoms during a submaximal exercise test in chronic heart failure, 287
GRAY G.A. *see* STRACHAN F.E.
GRINGAUZ A. & THOMSON A.H. Introduction to medicinal chemistry, 181
GROVES A. *see* ILETT K.F.
GUILLEMANT S. *see* BERLIN I.
GUTTHANN S.P. *see* GARCIA RODRIGUEZ L.A.

HA H.R. *see* KUPFERSCHMIDT H.H.T.
HÄGG S. *see* SPIGSET O.
HACKETT L.P. *see* ILETT K.F.
HACKETT L.P. *see* KRISTENSEN J.H.
HAI T.N. *see* SIDHU J.S.
HALIFAX K. *see* BARRY M.G.
HALIFAX K.L. *see* GENTILE D.M.
HALL I.P., GAZIS A.G., WHITE D.J., WHEATLEY A. & COCKCROFT J.R. Association of β_2-adrenoceptor polymorphism with vascular reactivity in humans, 510P
HALL R. *see* ROUTLEDGE P.A.
HALONEN K. *see* AHOKOSKI O.
HAND M.F. *see* NOON J.P.
HARDER S., THÜRMANN P.A. & UNGETHÜM W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients, 377
HARINASUTA T. *see* KARBWANG J.
HART C.A. *see* HOGGARD P.G.
HART C.A. *see* SALES S.D.
HAWKSWORTH G.M. *see* LOCK R.E.
HAY A.W.M. *see* WOLFF K.
HAYES P.C. *see* SHI Q.
HAYTER S. *see* BRETT S.E.
HEDGES A. *see* COLLIER D.J.
HERNÁNDEZ Y. *see* VÁZQUEZ M.
HERRMANN V. *see* MALERCZYK C.
HERZOG S. *see* GLEITER C.H.
HOEFNAGELS W.H.L. *see* VAN ASSELT D.Z.B.
HOGEMANN A. *see* MALERCZYK C.
HOGGARD B. *see* TURNER H.L.
HOGGARD P.G. *see* KEWN S.
HOGGARD P.G. *see* SALES S.D.
HOGGARD P.G., MANION V., BARRY M.G. & BACK D.J. Effect of protease inhibitors on nucleoside analogue phosphorylation *in vitro*, 165
HOGGARD P.G., SALES S.D., HART C.A., BARRY M. & BACK D.J. The effect of chronic HIV infection on the intracellular activation of nucleoside analogues *in vitro*, 517P
HOLGATE S.T. *see* BARDIN P.G.
HOLLENSTEIN U.M. *see* THALHAMMER F.
HOLMBERG J. *see* ANDERSSON T.
HOMER-VANNIASINKAM S. *see* CAVANAGH S.P.
HOMER-VANNIASINKAM S. *see* ESTDALE S.E.
HOTCHKISS S.A.M. *see* LIU F.C.
HOTCHKISS S.A.M., JAMESON H.L. & TONGE R.P. Dinitrochlorobenzene-mediated glutathione depletion in cultured human keratinocytes, 508P
HOUSER J. *see* LISTON T.E.
HOUSTON J.B. *see* CARLILE D.J.
HOUSTON J.B. *see* CHADWICK A.P.
HOUSTON J.B. *see* KENWORTHY K.E.
HOUSTON J.B. *see* NICHOLLS S.G.
HOUSTON J.B. *see* WITHEROW L.E.
HUANG S.L. *see* FENG H.J.
HUFSCHMID E. *see* WILDER-SMITH C.H.
HUGHES A. *see* PICKKERS P.
HUNG N.C. *see* BATTY K.T.
HUONG N.V. *see* SIDHU J.S.
HUUPPONEN R. *see* AHOKOSKI O.
HYLAND R. *see* ACKLAND M.

IACOB M. *see* JOANNIDES R.
IACOB M. *see* MOORE N.
ILETT K.F. *see* BATTY K.T.
ILETT K.F. *see* KRISTENSEN J.H.
ILETT K.F., HACKETT L.P., DUSCI L.J., ROBERTS M.J., KRISTENSEN J.H., PAECH M., GROVES A. & YAPP P. Distribution and excretion of venlafaxine and *O*-desmethylvenlafaxine in human milk, 459
IRJALA K. *see* AHOKOSKI O.
ISHIZAKI T. *see* KOBAYASHI K.

JACKSON P.R. *see* GHAHRAMANI P.
JAILLON P. *see* LECHAT P.
JAKUBETZ J., FUCHS B., GORF A., POLLER U., RADKE J. & BRODDE O.-E. Can human cardiac β_2-adrenoceptors undergo agonist-induced desensitization? An *in vivo* study in healthy volunteers, 509P
JAMESON H.L. *see* HOTCHKISS S.A.M.
JANATA K. *see* THALHAMMER F.
JARTTI T.T., KUUSELA T.J., KAILA K.U.O., TAHVANAINEN I.A.T. & VÄLMÄKI I.A.T. The dose-response effects of terbutaline on the variability, approximate entropy and fractal dimension of heart rate and blood pressure, 277
JEFFERIES T.M. *see* POTTS R.J.
JEFFERYS D.B.J., LEAKEY D., LEWIS J.A., PAYNE S. & RAWLINS M.D. New active substances authorized in the United Kingdom between 1972 and 1994, 151
JICK H. *see* JICK S.S.
JICK H. *see* MEIER C.R.
JICK S.S., VASILAKIS C., MARTINEZ C. & JICK H. A study of the relation of exposure to quinolones and suicidal behaviour, 77
JÖNSSON S. *see* NYBERG L.
JOANNIDES R. *see* MOORE N.
JOANNIDES R., MOORE N., IACOB M., COMPAGNON P., BACRI A.M. & THUILLEZ C. A comparison of the effects of amlodipine and verapamil on exercise performance and heart rate variability in healthy volunteers, 192P
JOANNIDES R., MOORE N., IACOB M., COMPAGNON P., PLAN D. &

THUILLEZ C. A comparison of the effects of short-acting nifedipine, amlodipine and diltiazem at rest and doing tilt and exercise in healthy volunteers, 199P
JOHNSON A. *see* LISTON T.E.
JOHNSTON A. *see* COLLIER D.J.
JONES B. *see* ACKLAND M.
JONES B. *see* McELHATTON P.R.
JONES B.C. *see* LOCK R.E.
JONES T.E., MORRIS R.G. & BACK D.J. Diltiazem affects CYP3A4 for longer than predicted, 208P
JONSSON E.N. *see* SIDHU J.S.
JURIMA-ROMET M., WRIGHT M. & NEIGH S. Terfenadine-antidepressant interactions: an *in vitro* inhibition study using human liver microsomes, 318
JUSKO W.J. *see* SHARMA A.

KAILA K.U.O. *see* JARTTI T.T.
KARBWANG J., NA-BANGCHANG K., TIN T., SUKONTASON K., RIMCHALA W. & HARINASUTA T. Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure, 597
KARLSSON M.O. *see* SIDHU J.S.
KARLSSON M.O., WADE J.R., LOUMAYE E. & MUNAFO A. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women, 13
KASKI J.C. *see* KROMER B.M.
KAWANO K. *see* MÜCK W.
KAYE C.M. *see* TAYLOR A.C.
KEIR D. *see* WYNNE H.A.
KELDER J.C. *see* DENEER V.H.M.
KENNA J.G. *see* SOMCHIT N.
KENNEDY B.M. *see* NYBERG L.
KENWORTHY K.E., CLARKE S.E., ANDREWS J. & HOUSTON J.B. Sigmoidal kinetics of CYP3A4: the simultaneous metabolism and binding of testosterone and diazepam, 520P
KERWIN R. *see* COTTER D.
KEWN S., HOGGARD P.G., VEAL G.J., BARRY M.G. & BACK D.J. The intracellular activation of ddI (didanosine) in combination with other nucleoside analogues *in vitro*, 518P
KIM N.V. *see* BATTY K.T.
KINGMA J.H. *see* DENEER V.H.M.
KITTERINGHAM N.R. *see* PIRMOHAMED M.
KIVISTÖ K.T. *see* LAMBERG T.S.
KLOTZ U. *see* FROMM M.F.
KOBAYASHI K., NAKAJIMA M., CHIBA K., YAMAMOTO T., TANI M., ISHIZAKI T. & KUROIWA Y. Inhibitory effects of antiarrhythmic drugs on phenacetin *O*-deethylation catalysed by human CYP1A2, 361
KRÄHENBÜHL S. *see* KUPFERSCHMIDT H.H.T.
KRISTENSEN J.H. *see* ILETT K.F.
KRISTENSEN J.H., ILETT K.F., DUSCI L.J., HACKETT L.P., YAPP P., WOJNAR-HORTON R.E., ROBERTS M.J. & PAECH M. Distribution and excretion of sertraline and *N*-desmethylsertraline in human milk, 453
KROEMER H.K. *see* FROMM M.F.
KROMER B.M. KASKI J.C., MURDAY A., MADDEN B. & TIPPINS J.R. Evidence for a role for the isoprostane 8-epi-prostaglandin $F_{2\alpha}$ in ischaemic heart disease, 197P
KROON J.M. *see* BURGGRAAF J.
KROON J.M. *see* VAN GERVEN J.M.A.
KUHN W. *see* GLEITER C.H.
KUPFERSCHMIDT H.H.T., FATTINGER K.E., HA H.R., FOLLATH F. & KRÄHENBÜHL S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man, 355
KUROIWA Y. *see* KOBAYASHI K.
KUTCHER D., BIRD D., ROBERTSON H.A., KUTCHER S.P. & DURSUN S.M. Effects of ageing on the prefrontal temporal cortical network function in healthy volunteers as assessed by 'COWA', 204P
KUTCHER S.P. *see* KUTCHER D.
KUUSELA T.J. *see* JARTTI T.T.

LAGUNA J.C. *see* VÁZQUEZ M.
LAMBERG T.S., KIVISTÖ K.T. & NEUVONEN P.J. Concentrations and effects of buspirone are considerably reduced by rifampicin, 381
LAMPE F.C. *see* BARDIN P.G.
LANGLEY R.W. *see* ABDELMAWLA A.H.
LANGLEY R.W. *see* BITSIOS P.
LAYTON G. *see* SOUL-LAWTON J.H.
LEAKER B.R. *see* SULTANA S.R.
LEAKEY D. *see* JEFFERYS D.B.J.
LEARY A. *see* SHIELS P.
LECAILLON J.B., GODBILLON J., CAMPESTRINI J., NAQUIRA C., MIRANDA L., PACHECO R., MULL R. & POLTERA A.A. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis, 601
LECHAT P., ESCOLANO S., JAILLON P., BOISSEL J.P. & MALLET A. Impact on survival of the bisoprolol-induced haemodynamic effects in the CIBIS trial, 198P
LECOINTRE D. *see* MOORE N.
LEES K.R. *see* MURRAY L.
LEGOUT V. *see* BERLIN I.
LEMAIRE M. *see* SIMON N.
LENEHAN T.J. *see* MILLAR A.W.
LENNARD L. *see* ROWLAND K.
LENNARD M.S. *see* GHAHRAMANI P.
LENNARD M.S. *see* ROSTAMI-HODJEGAN A.
LENNARD M.S. *see* SIMOOYA O.O.
LEREBOURS G. *see* MORRE N.
LEROUX B. *see* TRENQUE T.
LETTIS S. *see* YOUNG M.A.
LEVY M. *see* AZAZ-LIVSHITS T.
LEWIS J.A. *see* JEFFERYS D.B.J.
LIAN L-Y *see* DELGODA R.
LIE-A-HUEN L. *see* DENEER V.H.M.
LILLEYMAN J.S. *see* ROWLAND K.
LIM P. *see* SHIELS P.
LIP G.Y.H. *see* GIBBS C.R.
LIPWORTH B.J. & CLARK D.J. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer, 161
LIPWORTH B.J. *see* AZIZ I.
LIPWORTH B.J. *see* WILSON A.M.
LISTON T.E., CONKLYN M.J., HOUSER J., WILNER K.D., JOHNSON A., APSELOFF G., WHITEACRE C. & SHOWELL H.J. Pharmacokinetics and pharmacodynamics of the leukotriene B_4 receptor antagonist CP-105,696 in man following single oral administration, 115
LIU F.C. & HOTCHKISS S.A.M. *In vivo* metabolism of eugenol and isoeugenol following topical application in male F344 rats, 506P
LLOYD J. *see* BARRY M.G.
LOCK R.E., JONES B.C., SMITH D.A. & HAWKSWORTH G.M. Investigation of substrate structure activity relationships (SSAR) for cytochrome P450 2C19, 511P
LOCKER G.J. *see* THALHAMMER F.
LONG A. *see* WYNNE H.A.
LOPEZ-GILL A. *see* BREFEL, C.
LOUMAYE E. *see* KARLSSON M.O.
LOVESTONE S. *see* COTTER D.
LOWRY R.C. *see* NEWBY D.E.
LÜSCHER T.F. *see* WENZEL R.R.
LUDLAM C.A. *see* NEWBY D.E.
LYNCH K.P. *see* MILLAR A.W.

MABILLE M. *see* MOORE N.
MACCALLUM H., CHOWIENCZYK P.J., DAWES M., RITTER J.M. & ANGGARD E.E. Effect of inhaled salbutamol on the digital volume pulse wave in healthy men, 197P
MACDONALD C. *see* NING J.
MACDONALD T. *see* SHIELS P.
MADDEN B. *see* KROMER B.M.
MAGIN S.G. *see* MALERCZYK C.
MAHMOOD I. & CHAMBERLAIN N. A limited sampling method for the estimation of AUC and C_{max} of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product, 241
MAI J. *see* TRAN A.
MAI T.X. *see* BATTY K.T.
MAJMADAR A. *see* NEWBY D.E.
MALAURIE E. *see* SIMON N.
MALERCZYK G., FUCHS B., BELZ G.G., ROLL S., BUTZER R., BREITHAUPT-GRÖGLER K., HERRMANN V., MAGIN S.G., HOGEMANN A., VOITH B. & MUTSCHLER E. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man, 567
MALLET A. *see* LECHAT P.
MANION V. *see* HOGGARD P.G.
MANSON M.M. *see* GESCHER A.
MARTINEZ C. *see* JICK S.S.
MARX C. *see* TRENQUE T.

© 1998 Blackwell Science Ltd

MATHER L.E. *see* WOODHOUSE A.
MATTILA M.J. & VANAKOSKI J. Simulated driving in light and dark conditions: effects of alcohol and diazepam, 206P
McCREA J.B. *see* STRACHAN F.E.
McDONAGH T. *see* GRANT S.
McELHATTON P.R., BATEMAN D.N., COLLINS A., DONALDSON T.J.D., EVANS C., GORDON K.A., JONES B., PUGHE K.R., SMITH J.M., WORSLEY A.J. & YOUNG P.I. The national teratology information service (NTIS), 212P
McELHATTON P.R., BATEMAN D.N., EVANS C., PUGHE K.R. & WORSLEY A.J. Does prenatal exposure to ecstasy cause congenital malformations? A prospective follow-up of 92 pregnancies, 184P
McELHATTON P.R., BATEMAN D.N., EVANS C., PUGHE K.R. & WORSLEY A.J. The outcome of pregnancy following iron overdose by the mother, 212P
McFARLANE L.C. *see* AZIZ I.
McKILLOP D. *see* CHADWICK A.P.
McLEOD H.L. Clinically relevant drug-drug interactions in oncology, 539
McMURRAY J. *see* GRANT S.
MEIER B. *see* WENZEL R.R.
MEIER C.R. & JICK H. Tamoxifen and risk of idiopathic venous thromboembolism, 608
MEINDERS A.J. *see* VAN GERVEN J.M.A.
MENDEL C.M. *see* NEWBY D.E.
MENSIK C. *see* WOLZT M.
MERKUS F.W.H.M. *see* VAN ASSELT D.Z.B.
MERLOS M. *see* VÁZQUEZ M.
MERRY C. *see* BARRY M.G.
MICHEL M.C. *see* TAGUCHI K.
MILLAR A.W., BROWN P.D., MOORE J., GALLOWAY W.A., CORNISH A.G., LENEHAN T.J. & LYNCH K.P. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers, 21
MILLEDGE J.S. *see* COLLIER D.J.
MILLER A. *see* TAYLOR A.C.
MILLS N.L. *see* STRACHAN F.E.
MILLS S.Y. *see* BARNES J.
MINERS J.O. & BIRKETT D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism, 525
MIOLETTI S. *see* RABBONE I.
MIRANDA L. *see* LECAILLON J.B.
MONTASTRUC J.L. *see* BREFEL C.
MOORE J. *see* MILLAR A.W.
MOORE N. *see* JOANNIDES R.
MOORE N., JOANNIDES R., IACOB M., COMPAGNON P., VIOLET I., LEREBOURS G. & THUILLEZ C. Effects of pure bradycardic agent, S16257, at rest and during exercise in healthy volunteers: comparison with propranolol, 188P
MOORE N., LECOINTRE D., NOBLET C. & MABILLE M. Frequency and cost of serious adverse drug reactions in a department of general medicine, 301
MORRIS A.D. *see* PETRIE J.R.
MORRIS R.G. *see* JONES T.E.
MOSTERT M. *see* RABBONE I.
MÜCK W., UNGER S., KAWANO K. & AHR G. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin, 583
MUCKLOW J.C. Postgraduate education in clinical pharmacology and therapeutics, 339
MULCAHY F. *see* BARRY M.
MULCAHY F. *see* BARRY M.G.
MULL R. *see* LECAILLON J.B.
MUMFORD J.P. *see* TRAN A.
MUNAFO A. *see* KARLSSON M.O.
MURDAY A. *see* KROMER B.M.
MURRAY K. *see* SULTANA S.R.
MURRAY L., SQUIRE I.B., REID J.L. & LEES K.R. Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure, 559
MURRAY L.S. *see* PETRIE J.R.
MUTSCHLER E. *see* MALERCZYK C.

NA-BANGCHANG K. *see* KARBWANG J.
NAAS A. *see* SHIELS P.
NAKAJIMA M. *see* KOBAYASHI K.
NANHEKHAN L.V. *see* VAN GERVEN J.M.A.
NAQUIRA C. *see* LECAILLON J.B.
NEIGH S. *see* JURIMA-ROMET M.
NEUVONEN P.J. *see* LAMBERG T.S.
NEWBURY C.J. *see* POTTS R.J.
NEWBY D.E. *see* CRUDEN N.L.
NEWBY D.E. *see* STRACHAN F.E.
NEWBY D.E., SCIBERRAS D.G., FERRO C.J., MENDEL C.M., GERTZ B.J., MAJMADAR A., LOWRY R.C. & WEBB D.J. Antagonism of substance P-induced forearm vasodilation by the neurokinin type 1 receptor antagonist, L-754,030, 186P
NEWBY D.E., WRIGHT R.A., LUDLAM C.A., BOON N.A., FOX K.A.A. & WEBB D.J. Intra-arterial substance P is a potent stimulator for the release of tissue plasminogen activator in the human forearm: role of nitric oxide, 193P
NEWTON-SAVAGE F.A.O., BABOOLAL S., BRACCHI R., SMAIL S.A. & ROUTLEDGE P.A. Management of stable angina in the community: a survey of general practitioners in Wales, 186P
NICHOLLS G. & HOUSTON J.B. Product inhibition of phenytoin and diazepam metabolism *in vitro* and its significance in predicting intrinsic clearance *in vitro*, 519P
NICHOLSON E. *see* WYNNE H.A.
NILSSON B.S. *see* TALBOT J.C.C.
NILSSON M. *see* NYBERG L.
NING J., MACDONALD C. & GRANT M.H. Studies on the cytotoxicity of chromium in oestoblasts, 214P
NISHI S., SHINDO M., ABE J. & ASADA A. Clinical aspects of indocyanine green pharmacokinetics following portal vein administration, 41
NOBLE M.E.M. *see* DELGODA R.
NOBLET C. *see* MOORE N.
NOLL G. *see* WENZEL R.R.
NOON J.P., WALKER B.R., HAND M.F. & WEBB D.J. Studies with iontophorectic administration of drugs to human dermal vessels *in vivo*: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide, 545
NOTARIANNI L.J. *see* POTTS R.J.
NYBERG L. *see* BANG U.
NYBERG L., ROSENBORG J., WEIBULL E., JÖNSSON S., KENNEDY B.M. & NILSSON M. Pharmacokinetics of bambuterol in healthy subjects, 471

O'MAHONEY T. *see* TRAN A.
OLIVE G. *see* TRAN A.

PACHECO R. *see* LECAILLON J.B.
PAECH M. *see* ILETT K.F.
PAECH M. *see* KRISTENSEN J.H.
PAINTAUD G. *see* WAKELKAMP M.
PAPADOURIS D. *see* BERKOVITCH M.
PARKER A.C., PRITCHARD P., PRESTON T. & CHOONARA I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test, 176
PARKIN S.M. *see* CAVANAGH S.P.
PARKIN S.M. *see* ESTDALE S.E.
PART B.K. *see* PIRMOHAMED M.
PASTORINO U. *see* GESCHER A.
PAVORD I.D. *see* BENNETT J.A.
PAYNE S. *see* JEFFERYS D.B.J.
PECK R.W. *see* SOUL-LAWTON J.H.
PELLING C.W.A. *see* COLLIER D.J.
PETRIE J.R., UEDA S., MORRIS A.D., MURRAY L.S., ELLIOTT H.L. & CONNELL J.M.C. How reproducible is bilateral forearm plethysmography?, 131
PICCININI M. *see* RABBONE I.
PICKKERS P., RUSSEL F., HUGHES A. & SMITS P. Direct vascular effects of acetazolamide in humans, 510P
PIETERS M.S.M. *see* VAN GERVEN J.M.A.
PINON J.M. *see* TRENQUE T.
PINTO R. *see* BHATHENA R.K.
PIRMOHAMED M., GILL H.J., TJIA J., KITTERINGHAN N.R., BACK D.J. & PARK B.K. Effect of CYP2C9*2 genetic polymorphism on the bioactivation of sulphamethoxazole, 504P
PLAN D. *see* JOANNIDES R.
PLUMMER S.M. *see* GESCHER A.
POLLER U. *see* JAKUBETZ J.
POLTERA A.A. *see* LECAILLON J.B.
POSNER J. *see* SOUL-LAWTON J.H.
POTTS R.J., JEFFERIES T.M., NEWBURY C.J., SMITH G. & NOTARIANNI L.J. Changes in chromatin structure in sperm from smokers, 184P
POWELL S.M. *see* BATTY K.T.
PRESTON T. *see* PARKER A.C.

PRITCHARD P. *see* PARKER A.C.
PROOST J.H. *see* DENEER V.H.M.
PUECH A.J. *see* BERLIN I.
PUGHE K.R. *see* McELHATTON P.R.
PURKISS A.G., CHARLETT A., WELLER C., DOBBS S.M. & DOBBS R.J. Association of serum immunoglobulin subclasses IgA1 and IgA2 with facets of Parkinsonism in patients and controls, 207P
PYYKKÖ K. *see* BITSIOS P.

QUEREUX C. *see* TRENQUE T.

RABBONE I., PICCININI M., CURTO M., MOSTERT M., GAMBA S., MOLLETTI S., BRUNO R. & RANAUDO M.T. Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus, 291
RABELINK T.J. *see* STRACHAN F.E.
RADKE J. *see* JAKUBETZ J.
RAMSAY L.E. *see* GHAHRAMANI P.
RANE A. Endocrine and adrenergic pharmacological intervention in diseases of the prostate, 329
RASCOL O. *see* BREFEL C.
RAWLINS M. *see* WALLEY T.
RAWLINS M.D. *see* JEFFERYS D.B.J.
RAWSTRON A. *see* CAVANAGH S.P.
RAYET S. *see* BREFEL C.
REED A. *see* ESTDALE S.E.
REID J.L. *see* MURRAY L.
REVELEY M.A. *see* DURSUN S.M.
REY E. *see* TRAN A.
RICHARDS D.A. *see* TURNER H.L.
RICHENS A. *see* ROUTLEDGE P.A.
RIMCHALA W. *see* KARBWANG J.
RINAUDO M.T. *see* RABBONE I.
RITTER J.M. *see* BRETT S.E.
RITTER J.M. *see* FISHER A.
RITTER J.M. *see* MacCALLUM H.
RIZZO L.F.L. *see* SERRA H.A.
RÖHSS K. *see* KRISTENSEN J.H.
ROBERTS M.J. *see* ANDERSSON T.
ROBERTS M.J. *see* ILETT K.F.
ROBERTSON H.A. *see* KUTCHER D.
ROBINSON P. *see* FISHER A.
ROBSON S.C. *see* ANUMBA D.O.C.
RODGERS E.H. & GRANT M.H. Inducing agents alter the cytotoxic response of MCF7 cells to mitoxantrone, 213P
ROLL S. *see* MALERCZYK C.
ROS E. *see* VÁZQUEZ M.
ROSENBERG M.E. *see* COLLIER D.J.
ROSENBORG J. *see* BANG U.
ROSENBORG J. *see* NYBERG L.
ROSTAMI-HODJEGAN A. *see* WOLFF K.
ROSTAMI-HODJEGAN A., LENNARD M.S., WOODS H.F. & TUCKER G.T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease, 504P
ROUTLEDGE P.A. *see* BESA C.
ROUTLEDGE P.A. *see* NEWTON-SAVAGE F.A.O.
ROUTLEDGE P.A., SORYAL I., EVE M.D., WILLIAMS J., RICHENS A. & HALL R. Reduced bioavailability of nifedipine in patients with epilepsy receiving anticonvulsants, 196P
ROWLAND K., LENNARD L. & LILLEYMAN J.S. The *in vitro* metabolism of 6-mercaptopurine by human liver cytosol, 518P
RUSSEL F. *see* PICKKERS P.
RUSSEL F.G.M. *see* VAN ASSELT D.Z.B.
RUSSEL F.G.M. *see* ZANDBERGEN E.

SADAN B. *see* AZAZ-LIVSHITS T.
SALES S.D. *see* HOGGARD P.G.
SALES S.D., HOGGARD P.G., HART C.A. & BACK D.J. The effect of chronic HIV infection on the cytotoxicity of antiretrovial agents *in vitro*, 516P
SALMINEN E. *see* AHOKOSKI O.
SCHÄFERS R.F. *see* TAGUCHI K.
SCHEININ H. *see* AHOKOSKI O.
SCHEININ M. *see* BITSIOS P.
SCHEMETTERER L. *see* WOLZT M.
SCHOEMAKER H.C. *see* FAAIJ R.A.
SCHOEMAKER R.C. *see* BURGGRAAF J.
SCHOEMAKER R.C. *see* VAN GERVEN J.M.A.
SCHOEMAKER R.C., BURGGRAAF J. & COHEN A.F. Assessment of hepatic blood flow using continuous infusion of high clearance drugs, 463
SCHOLLNHAMMER G. *see* BERLIN I.
SCHOLZE J., ZILLES P. & COMPAGNONE D. ON BEHALF OF THE GERMAN HYPERTENSION STUDY GROUP, Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design, 491
SCHREEB K.H. *see* GLEITER C.H.
SCIBERRAS D.G. *see* NEWBY D.E.
SCIBERRAS D.G. *see* STRACHAN F.E.
SERRA H.A., ALVES O., RIZZO L.F.L., DEVOTO F.M. & ASCIERTO H. Loratadine—pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial, 147
SHALIT M. *see* AZAZ-LIVSHITS T.
SHARMA A. & JUSKO W.J. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses, 229
SHAW D. *see* BERKOVITCH M.
SHENFIELD G.M. Integrating clinical pharmacology teaching with general practice, 393
SHI Q., HAYES P.C. & GRANT M.H. Effects of serum from patients with acute liver failure on the growth of HepG2 cells, 214P
SHIELS P., NAAS A., LIM P., LEARY A. & MACDONALD T. The ELITE study, 614
SHINDO M. *see* NISHI S.
SHOWELL H.J. *see* LISTON T.E.
SIDHU J.S., ASHTON M., HUONG N.V., HAI T.N., KARLSSON M.O., SY N.D., JONSSON E.N. & CONG L.D. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria, 347
SIEGERT C. *see* FAAIJ R.A.
SIJUMBIL G. *see* SIMOOYA O.O.
SIM E. *see* DELGODA R.
SIMON N., DAILLY E., COMBES O., MALAURIE E., LEMAIRE M., TILLEMENT J.P. & URIEN S. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, 173
SIMOOYA O.O., SIJUMBIL G., LENNARD M.S. & TUCKER G.T. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians, 315
SIMOOYA O.O., SIJUMBIL G., LENNARD M.S. & TUCKER G.T. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians, 513P
SINCLAIR J.C. *see* DELGODA R.
SJAHID S.I., VAN DER LINDEN P.D. & STRICKER B.H.C. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study, 591
SMAIL S.A. *see* NEWTON-SAVAGE F.A.O.
SMITH D. *see* ACKLAND M.
SMITH D.A. *see* LOCK R.E.
SMITH G. *see* POTTS R.J.
SMITH J.M. *see* McELHATTON P.R.
SMITS P. *see* PICKKERS P.
SMITS P. *see* ZANDBERGEN E.
SÖDERSTRÖM E. *see* SPIGSET O.
SOMCHIT N., WADE L.T., GOLDIN R.D., KENNA J.G. & CALDWELL J. Sulindac-association injury: an animal model? 506P
SORYAL I. *see* ROUTLEDGE P.A.
SOUL-LAWTON J.H., WEATHERLEY B.C., POSNER J., LAYTON G. & PECK R.W. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin, 87
SPIGSET O., GRANBERG K., HÄGG S., SÖDERSTRÖM E. & DAHLQVIST R. Non-linear fluvoxamine disposition, 257
SQUIRE I.B. *see* MURRAY L.
STEIN K. *see* WALLEY T.
STIEKEMA J. *see* FAAIJ R.A.
STRACHAN F.E. *see* CRUDEN N.L.
STRACHAN F.E., CROCKETT T.C., MILLS N.L., GRAY G.A. & WEBB D.J. A comparison of the effects of two ET_B receptor agonists in forearm resistance and capacitance vessels *in vivo*, 195P
STRACHAN F.E., GRAY G.A. & WEBB D.J. Antagonism of ET_B-mediated venoconstriction by BQ-788 in human veins *in vivo*, 194P
STRACHAN F.E., NEWBY D.E., SCIBERRAS D.G., McCREA J.B., GOLDBERG M.R. & WEBB D.J. Reproducibility of forearm vasoconstriction to intra-arterial endothelin-1, 194P

© 1998 Blackwell Science Ltd

STRACHAN F.E., VERHAAR M.C., NEWBY D.E., RABELINK T.J. & WEBB D.J. Blockade of ET_A receptor increases endogenous nitric oxide generation, 187P
STRICKER B.H.C. *see* SJAHID S.I.
STRUTHERS A.D. *see* Yee K.M.
SUKONTASON K. *see* KARBWANG J.
SULTANA S.R., MURRAY K., CRAGGS M.D., WYLLIE M.G. & LEAKER B.R. α_1-adrenoceptor antagonist selectivity determined by simultaneous blood pressure and long-term uretheral pressure monitoring in men, 191P
SUNDER-PLASSMANN G. *see* THALHAMMER F.
SWENSON E.R. *see* COLLIER D.J.
SY N.D. *see* SIDHU J.S.
SZABADI E. *see* ABDELMAWLA A.H.
SZABADI E. *see* BITSIOS P.
SZEMIS A. *see* DURSUN S.M.

TACK C.J.J. *see* ZANDBERGEN E.
TAGUCHI K., SCHÄFERS R.F. & MICHEL M.C. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics, 49
TAHVANAINEN I.A.T. *see* JARTTI T.T.
TALBOT J.C.C. & NILSSON B.S. Pharmacovigilance in the pharmaceutical industry, 427
TAN K.S. *see* AZIZ I.
TANI M. *see* KOBAYASHI K.
TARIQ S. *see* BESA C.
TATTERSFIELD A.E. *see* BENNETT J.A.
TAVERNOR S. *see* BITSIOS P.
TAYLOR A.C. *see* BREFEL C.
TAYLOR A.C., BEERAHEE A., CITERONE D.R., MILLER A., FUELL D. & KAYE C.M. Linear pharmacokinetics of ropinirole in patients with Parkinson's disease, 204P
TEMKIN N.R. *see* ANDERSON G.D.
THALAMAS C. *see* BREFEL C.
THALHAMMER F., HOLLENSTEIN U.M., LOCKER G.J., JANATA K., SUNDER-PLASSMANN G., FRASS M. & BURGMANN H. Azithromycin-related toxic effects of digitoxin, 91
THIEN H.V. *see* BATTY K.T.
THOMAS S.M.L. *see* DRICI M-D.
THOMPSON COON J. *see* BENNETT J.A.
THOMSON A.H. *see* GRINGAUZ A.
THORMANN W. *see* WILDER-SMITH C.H.
THU L.T.A. *see* BATTY K.T.
THÜRMANN P.A. *see* HARDER S.
THUILLEZ C. *see* JOANNIDES R.
THUILLEZ C. *see* MOORE N.
TIEN N.P. *see* BATTY K.T.
TILLEMENT J.P. *see* SIMON N.
TIN N. *see* DURSUN S.M.
TIN T. *see* KARBWANG J.
TIPPINS J.R. *see* KROMER B.M.
TJIA J. *see* PIRMOHAMED M.
TJIA J.F. *see* EAGLING V.A.
TOMLINSON B. *see* BENZIE I.F.F.
TONGE R.P. *see* HOTCHKISS S.A.M.
TRAN A., O'MAHONEY T., REY E., MAI J., MUMFORD J.P. & OLIVE G. Vigabatrin: placental transfer *in vivo* and excretion into breast milk of the enantiomers, 409
TRENQUE T., MARX C., QUEREUX C., LEROUX B., DUPOUY D., DORANGEON P.H., CHOISY H. & PINON J.M. Human maternofoetal distribution of pyrimethamine-sulphadoxine, 179
TUCKER G.T. *see* GHAHRAMANI P.
TUCKER G.T. *see* ROSTAMI-HODJEGAN A.
TUCKER G.T. *see* SIMOOYA O.O.
TUCKER G.T. *see* WOLFF K.
TURNER H.L., RICHARDS D.A., BOWERY N.G., HOGGART B. & CHONG S. Increased glutamate concentration in CSF of patients with chronic arthritic pain, 208P
TYMAN C. *see* ACKLAND M.

UCHIDA E. *see* VAN GERVEN J.M.A.
UEDA S. *see* PETRIE J.R.
UGURLUOGLU A. *see* WOLZT M.
UNGER S. *see* MÜCK W.
UNGETHÜM W. *see* HARDER S.
URIEN S. *see* SIMON N.

VÁZQUEZ M., ZAMBÓN D., HERNÁNDEZ Y., ADZET T., MERLOS M., ROS E. & LAGUNA J.C. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia, 265
VÄLMÄKI I.A.T. *see* JARTTI T.T.
VALLANCE P. Nitric oxide in the human cardiovascular system—SKB Lecture 1997, 433
VAN ASSELT D.Z.B., MERKUS F.W.H.M., RUSSEL F.G.M. & HOEFNAGELS W.H.L. Nasal absorption of hydroxocobalamin in healthy elderly adults, 83
VAN DER LINDEN P.D. *see* SJAHID S.I.
VAN GERVEN J.M.A., UCHIDA E., PIETERS M.S.M., MEINDERS A.J., SCHOEMAKER R.C., NANHEKHAN L.V., KROON J.M., ALTORF B., YASUDA K. & COHEN A.F. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy male and female volunteers, 211P
VANAKOSKI J. *see* MATTILA M.J.
VASILAKIS C. *see* JICK S.S.
VEAL G.J. *see* KEWN S.
VERHAAR M.C. *see* STRACHAN F.E.
VERVOORT G. *see* ZANDBERGEN E.
VIBY-MOGENSEN J. *see* BANG U.
VIOLET I. *see* MOORE N.
VOITH B. *see* MALERCZYK C.

WADE J.R. *see* KARLSSON M.O.
WADE L.T. *see* SOMCHIT N.
WAKELKAMP M., ALVÁN G. & PAINTAUD G. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide, 63
WALAN A. *see* ANDERSSON T.
WALKER B.R. *see* NOON J.P.
WALLER P.C. Pharmacovigilance: towards the next millenium, 417
WALLEY T., RAWLINS M. & STEIN K. Health technology assessment — the role of the pharmaceutical panel, 217
WANG W. *see* FENG H.J.
WANG W.X. *see* DRICI M-D.
WARD A. *see* WYNNE H.A.
WAROT D. *see* BERLIN I.
WEATHERLEY B.C. *see* SOUL-LAWTON J.H.
WEBB D.J. *see* CRUDEN N.L.
WEBB D.J. *see* NEWBY D.E.
WEBB D.J. *see* NOON J.P.
WEBB D.J. *see* STRACHAN F.E.
WEEKES L.M., BROOKS C. & DAY R.O. Indicators for Drug and Therapeutics Committees, 393
WEIBULL E. *see* NYBERG L.
WELLER C. *see* PURKISS A.G.
WENZEL R.R., ZBINDEN S., NOLL G., MEIER G. & LÜSCHER T.F. Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide, 441
WHEATLEY A. *see* HALL I.P.
WHITE D.J. *see* HALL I.P.
WHITEACRE C. *see* LISTON T.E.
WILDER-SMITH C.H., HUFSCHMID E. & THORMANN W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine, 575
WILDING P.J. *see* BENNETT J.A.
WILLIAMS J. *see* ROUTLEDGE P.A.
WILLOUGHBY M. *see* BARNES J.
WILNER K.D. *see* LISTON T.E.
WILSON A.M. & LIPWORTH B.J. A chronic dosing comparison of the systemic bioactivity with oral prednisolone and nebulized budesonide in adult asthmatic patients, 185P
WINN H.R. *see* ANDERSON G.D.
WITHEROW L.E. & HOUSTON J.B. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in rat microsomes and isolated hepatocytes to predict *in vivo* clearance, 519P
WOJNAR-HORTON R.E. *see* KRISTENSEN J.H.
WOLFF K., ROSTAMI-HODJEGAN A., HAY A.W.M., CALVERT R. & TUCKER G.T. Population pharmacokinetics of methadone in opiate users: adaptive changes in kinetics from single dose to steady state, 514P
WOLZT M., UGURLUOGLU A., SCHMETTERER L., DORNER G., ZANASCHKA G., MENSIK C. & EICHLER H.G. Exogenous L-arginine

does not affect angiotensin II-induced renal vasoconstriction in man, 71
WOODHOUSE A. & MATHER L.E. The effect of duration of dose delivery with patient-controlled analgesia on the incidence of nausea and vomiting after hysterectomy, 57
WOODS H.F. *see* ROSTAMI-HODJEGAN A.
WOOSLEY R.L. *see* DRICI M-D.
WORSLEY A.J. *see* McELHATTON P.R.
WRIGHT M. *see* JURIMA-ROMET M.
WRIGHT R.A. *see* NEWBY D.E.
WYLLIE M.G. *see* SULTANA S.R.
WYNNE H.A., LONG A., NICHOLSON E., WARD A. & KEIR D. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?, 405

YAMAMOTO T. *see* KOBAYASHI K.
YAPP P. *see* ILETT K.F.
YAPP P. *see* KRISTENSEN J.H.
YASUDA K. *see* VAN GERVEN J.M.A.
YEE K.M. & STRUTHERS A.D. Aldosterone causes baroreceptor dysfunction in man, 189P
YEO W.W. *see* GHAHRAMANI P.
YOUNG M.A., LETTIS S. & EASTMOND R. Concomitant administration of colestyramine influences the absorption of troglitazone, 37
YOUNG M.A., LETTIS S. & EASTMOND R. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food, 31
YOUNG P.I. *see* McELHATTON P.R.

ZAMBÓN D. *see* VÁZQUEZ M.
ZANASCHKA G. *see* WOLZT M.
ZANDBERGEN E., VERVOORT G., TACK C.J.J., RUSSEL F.G.M. & SMITS P. The role of adenosine in the vasodilator response to insulin in humans, 511P
ZBINDEN S. *see* WENZEL R.R.
ZHOU H.H. *see* FENG H.J.
ZILLES P. *see* SCHOLZE J.

SUBJECT INDEX

This index was compiled from the keywords

ACE inhibitor, 377
ACE inhibitors, 168, 559
ACTH, 210P
Abdominal aortic aneurysm, 522P
Absorption, 21
Acetazolamide, 510P
Acetylation, 504P
Acetylcholine, 545
Active metabolite, 601
Acute mountain sickness, 200P
Acute renal failure, 597
Adenosine, 511P
Adenosine monphosphate, 201P
α-adrenoceptor blockade, 329
α_1-adrenoceptor antagonist, 191P
α_1-adrenoceptor subtypes, 49
Adverse drug reaction reporting system, 496
Adverse drug reaction, 257
Adverse drug reactions, 301, 309, 427
Adverse events, 427
Ageing, 204P
Airomir, 160
Alcohol, 206P
Aldosterone, 189P
Allergen, 387
5-α-reductase inhibition, 329
Alternative medicine, 496
Amitriptyline, 507P
Amlodipine, 192P, 199P
Angina, 191P
Angiotensin II antagonists, 567
Angiotensin II, 71
Antinociception, 575
Antioxidant, 168
Antipsychotic drugs, 192P
Antipyrine, 202P
Antiretroviral agents, 516P
Antiretroviral therapy, 221
Antithrombotic agent, 211P
Approximate entropy, 277
Aromatase inhibition, 141
Artemether, 597
Artemisinin, 347
Artesunate, 123
Arthritis, 208P
Arylamine-*N*-acetyltransferases, 504P
Aspirin, 323, 545
Asthma, 190P, 387, 402
Atrial fibrillation, 485
Atrial flutter, 485
Atypical plasma cholinesterase, 479
Autonomic nervous system, 277
Azithromycin, 91

β-adrenoceptors, 271
β- and γ-catenins, 203P
β_2-adrenoceptor, 201P, 509P, 510P
BPH, 329
BQ-3020, 195P
BQ-788, 194P
Bambuterol, 471, 479
Baroreceptor function, 189P
Benign prostatic hyperplasia, 329
6β-hydroxycortisol, 101
Binding, 173
Bioactivity, 190P
Bioavailability, 123, 196P, 355, 471, 601
Bisoprolol, 198P, 271
Black, 583
Blood flow, 190P
Blood pressure variability, 277
Bradycardia, 188P
Brain injury, 101
Breast milk, 409
Budesonide, 190P, 201P
Buspirone, 381

CD11b, 115
CHD, 168
CIBIS trial, 198P
Caffeine breath test, 176
Caffeine, 176
Cancer chemoprevention, 1
Cancer chemotherapy, 539
Capillary blood, 347
Captopril, 168, 447, 614
Carbamazepine, 176, 241
Carbonic anhydrase inhibitors, 200P
Cardiovascular drugs, 591
Case-control, 77
Caucasians, 583
Cerebrospinal fluid, 208P
Cerivastatin, 583
Children, 147, 176
Chloroquine, 315, 513P
Cholesterol, 205P
Cholestyramine, 37
Chromatin, 189P
Chromium, 214P
Chronic heart failure, 287
Circulating lymphocytes, 291
Cisapride, 485
Clinical pharmacology and therapeutics, 339
Clinical pharmacology, 399
Clinical pharmacy, 339
Clinical trials, 523P
Clozapine, 205P
Combination therapy, 491
Combined hyperlipidaemia, 265
Computerized healthcare database, 419
Congenital malformations, 184P
Congestive heart failure, 559
Continous infusion, 463
Continuing medical education, 339
Controlled word association test, 204P
Converting enzyme inhibition, 190P
Cortisol, 101, 210P
Creatinine clearance, 209P
Crossover-trial, 147
Curcumin, 1
Cyclosporin, 208P
Cystic fibrosis, 202P
CYP1A2, 176, 257, 361
CYP2C, 515P
CYP2C9, 512P, 525
CYP2C9*2, 503P
CYP2D6, 257, 503P, 513P
CYP2D6 inhibition, 315
CYP3A, 519P
CYP3A4, 318, 355, 516P, 520P
Cytochrome P450, 107, 525
Cytochrome P450 2C19, 511P
Cytochrome P450 2D6, 575
Cytochrome P450 IIIA4, 208P
Cytochrome P450 inhibition, 107
Cytochrome P450A4, 515P
Cytokine assay kits, 523P
Cytokine response, 521P
Cytotoxicity, 214P

Deconvolution, 13
Desensitisation, 509P
Desogestrel, 515P
Dextromethorphan, 519P
Diazepam, 206P, 519P, 520P
Didanosine, 518
Differential selectivity, 107
Digital volume pulse wave, 197P
Digitoxin, 91
Digoxin, 87
Dihydroartemisinin, 123, 597
Dihydrocodeine, 575
Dihydromorphine, 575
Diltiazem, 199P, 208P
Dinitrochlorobenzene, 508P
Dipyridamole, 323
Disposition, 257
Dopaminergic agonist, 412
Dorsal hand vein, 271
Dosage regimens, 57
Dose-effect curves, 567
Dose-response study, 491
Driving, 206P
Drug interactions, 164, 525, 539
Drug metabolism, 504P, 525
Drug monitoring, 496
Drug safety, 427
Drug surveillance, 309
Drugs, 496

ELITE study, 614
ET_A receptor, 187P, 192P
ET_B receptor, 192P, 194P
ET_B receptor agonists, 195P
Echo-Doppler, 447
Ecstasy, 184P
Editorial, 93
Education, 339
Eformoterol, 201P
Elderly volunteers, 83
Enantiomers, 409
Endothelin-1, 192P, 194P, 441
Endothelium, 545
Enzyme induction, 176, 247
Epilepsy, 196P
Episodic treatment, 485
Erythropoietin, 157
Essential hypertension, 491
Ethnic groups, 583
Ethnicity, 211P, 513P
Eugenol, 506P
Exercise, 190P, 199P, 463
Exercise performance, 192P
Exercise testing and symptoms, 287

© 1998 Blackwell Science Ltd

FRAP assay, 168
Falciparum malaria, 123
Fasciola hepatica, 601
Fatty acids, 265
Fenoterol, 157
First dose hypotension, 559
Fluconazole, 521P
Fluoxetine, 210P, 318
Fluvoxamine, 257
Follicle stimulating hormone, 13
Food, 31, 601
Food interaction, 412
Forearm blood flow, 131
Forearm vasoconstriction, 194P
Formoterol, 201P
Fractal dimension, 277
Frusemide, 63

Gastrointestinal bleeding, 405
Gemfibrozil, 265
Gene, 27
General Practitioners, 191P
General practice, 399
Genetic polymorphism, 507P
Genistein, 1
Glutamate, 208P
Glutathione depletion, 508P
Glycoprotein IIb/IIIa receptors, 196P
Grapefruit juice, 355

HIV, 221, 335
HIV infection, 516P, 517P
HIV patients, 501
HIV protease inhibitor, 516P
HMG-CoA reductase inhibitor, 583
Half-life, 21
Halofantrine, 315, 513P
Health technology assessment, 217
Healthy subjects, 485
Heart failure, 614
Heart rate variability, 192P, 277
HepG2 cells, 214P
Hepatic blood flow, 463
Herbal medicines, 496
Hippocampus, 203P
Homoeopathy, 613
Hospital information systems, 309
Hospital pharmacoepidemiology, 309
Human immunodeficiency virus, 164
Human liver cytosol, 518P
Human liver microsomes, 318, 361
Human maternofoetal distribution, 179
Human milk, 453, 459
Human placenta lactogen, 157
Human skin, 441
Hydroxocobalamin (vitamin B12) nasal spray, 83
4′-hydroxylase, 27
Hypertension, 168

ICG clearance, 447
Idiopathic, 608
Imidapril, 377
Indicators, 393
Indirect response models, 229
Indocyanine green, 41, 463
Infant dose, 453, 459
Insulin, 511P
Interaction, 31, 37, 355, 381, 485
Intracellular metabolism, 164
Intrinsic clearance, 41, 512P, 519P
Iontophoresis, 545
Ipsapirone, 210P
Iron, 212P
Ischaemic heart disease, 197P
Isoeugenol, 506P
Isoprostane, 197P
Isoprostane 8-epi-prostaglandin $F_{2\alpha}$, 197P

Japanese, 583

Keratinocytes, 508P
Ketoconazole, 521P
3-ketodesgestrel, 515
Kinetics, 601

L-754,030, 191P
L-N^G-monomethylarginine, 545
LDL oxidation, 265
Lansoprazole, 369
Leukotriene B_4, 115
Lignocaine, 202P
Limb salvage surgery, 521P
Limited sampling, 241
Lipoprotein, 173
Liver blood flow, 447
Liver failure, 214P
Loratadine-pseudoephedrine, 147
Losartan, 614
Lovastatin, 265
Lung cancer, 503P
Lung delivery, 160
Lung function, 402

m1-mutations, 27
MCF7 cells, 213P
MDR reversion, 173
MPV-2213ad, 141
Malaria, 347
Marimastat, 21
Maternofoetal distribution, 179
Mechanisms, 1
Medical, 339
Medication, 591
Medroxyprogesterone acetate, 170
6-mercaptopurine, 518P
Metabolism, 101, 575
Metalloproteinase inhibitors, 21
Methadone, 514P
Metoprolol, 157
Mexiletine, 361
Michaelis-Menten kinetics, 512P
Milk : plasma ratio, 459
Mitoxantrone, 213P
Moclobemide, 551
Monoamine oxidase, 551
Multi-factorial design, 491

N-desmethylsertraline, 453
NIDDM, 291
NSAIDs, 405
Nadolol, 271
Nasal absorption, 83
National teratology information service, 212P
NebuChamber, 160
Nebuliser, 160
Nefazodone, 318
Neurokinin type 1 receptor, 191P
Neutrophil, 115
New active substances, 151
New biological substances, 151
New biotechnology agents, 151
New chemical entities, 151
Nifedipine, 194P, 199P, 447
Nitric oxide, 190P, 193P, 441
Nitric oxide physiology, 71
No interaction, 87
Nociceptive fibres, 441
Non-CFC, 160
Non-linear, 257
Non-linear dynamics, 277
Nonprescription, 496
Noradrenaline, 271
Nortriptyline, 507P
Nucleoside analogues, 517P

O-deethylation, 361
Ocreotide, 463
Older people, 247
Omeprazole, 369
Oral contraceptive, 515P
Org31540/SR90107A, 211P
Osteoblasts, 214P
Osteoporosis, 95
Overdose, 212P
Oxidative stress, 168

Paediatrics, 347
Pain, 575
Pantoprazole, 369
Parkinson's disease, 204P, 206P, 412, 510P
Patient controlled analgesia, 57
Patients, 601
Penicillin, 605
Pharmaceutical industry, 427
Pharmaceutical panel, 217
Pharmacodynamics, 63, 115, 123, 211P, 229, 247, 377, 539
Pharmacoepidemiology, 419, 427
Pharmacogenetics, 525
Pharmacokinetics, 21, 31, 37, 57, 63, 115, 123, 202P, 204P, 211P, 247, 257, 355, 369, 377, 381, 405, 412, 471, 479, 485, 507P, 539, 583, 597
Pharmacovigilance, 417, 419, 427
Pharmacy and Therapeutics Committees, 393
Pharmacy drugs, 591
Phase I study, 141
Phenacetin, 361
Phenytoin, 202P, 519P
Phosphodiesterase inhibitors, 387
Placebo, 147
Placenta, 409
Plasma binding, 173
Plasma cholinesterase, 471
Plasma cobalamin concentrations, 83
Platelets, 196P, 323
Plethysmography, 131
Polymorphism, 503P, 510P
Population pharmacokinetics, 13, 347, 514P
Portal vein, 41
Postoperative nausea and vomitting, 57
Prediction of AUC and C_{max}, 241
Prednisolone, 190P
Prefrontal temporal cortical network, 204P
Pregnancy, 189P, 190P, 212P
Prehepatic metabolism, 247
Prescribing, 339

© 1998 Blackwell Science Ltd

Primary care, 339
Product licenses, 151
Propafenone, 361
Prophylactic penicillin, 605
Propranolol, 188P
Prostacyclin, 190P, 545
Prostate cancer, 329
Protease inhibitor, 355
Protein binding, 202P
Pupil diameter, 551
Pyrimethamine, 179
Pyrimethamine-sulphadoxine, 179
Pyruvate dehydroxygenase, 291

QT interval, 192P
Quinidine, 575
Quinolone, 77

ROS, 168
Radioceptor assay, 49, 567
Receptor antagonist, 115
Regression analysis, 559
Renal function, 211P
Reproducibility, 71, 131, 194P
Research, 419
Retinoids, 1
Rifampicin, 27, 247, 381
Risk-benefit, 427
Ropinirole, 204P, 412

S-mephenytoin, 27
S16257, 188P
SDZ-PSC 833, 173
Safety withdrawals, 151
Safety, 21
Salbutamol, 160, 197P, 201P
Saquinavir, 355, 501, 516P
Sarafotoxin S6c, 195P
Schild regression technique, 567
Schizophrenia, 203P, 205P
Secondary care, 339
Selegiline, 551
Sertraline, 318, 453
Serum immunoglobulins, 207P
Serum lipids and lipoproteins, 170
Severe malaria, 597
Sickle cell disease, 605
Sidestream, 160
Sigmoidal kinetics, 519P, 520P
Smokers, 189P
Somatic, 575
Somatostatin, 463
Sorbitol, 463
Sotalol, 485
Spacer, 160
Spectral analysis, 277
Sperm, 189P
Sublingual, 485
Substance P, 191P, 193P
Substrate structure activity relationships, 511P
Suicide, 77
Sulindac, 505P
Sulphamethoxazole, 503P
Sulphonylureas, 291
Supraventricular tachycardia, 485
Survival, 198P

Tamoxifen, 608
Tamsulosin, 49
Teaching, 399
Terazosin, 49
Terbutaline, 277, 471, 479
Terfenadine, 318, 513P
Testosterone, 520P
Theophylline withdrawal, 402
Therapeutic drug monitoring, 501
Thrombosis, 323
Tilt, 199P
Tirofiban, 196P
Tissue plasminogen activator, 193P
Tocolysis, 157
Trandolapril, 491
Transdermal oestrogen therapy, 170
Transfer, 409
Troglitazone, 31, 37
Tyramine, 551

Urethral pressure monitoring, 191P

Valacicovir, 87
Valproate, 101
Vascular reactivity, 510P
Vasodilatation, 511P
Venlafaxine, 459
Venous thromboembolism, 608
Verapamil, 192P, 247, 491
Vigabatrin, 409
Visceral, 575
Volumatic, 160

Women, 13

Zambians, 315